ABCA5 Genotype

Your genes carry instructions for thousands of proteins that quietly run your biology, and ABCA5 (ATP-binding cassette transporter A5) is one of them. This gene encodes a protein that sits inside small recycling pouches in your cells, where it helps move cholesterol and keep those pouches working properly.

This is a research-stage genetic test. It does not yet carry the kind of standardized clinical cutpoints that established markers like LDL cholesterol or HbA1c do, but a baseline read on your inherited variant can give you a one-time piece of information you can revisit as the science matures.

What This Gene Actually Does

ABCA5 belongs to a large family of cellular transporters that use energy to push molecules across membranes. Within this family, the ABCA branch is particularly tied to moving fats and cholesterol around inside cells. ABCA5 specifically sits in lysosomes (small internal recycling compartments) and helps regulate cholesterol traffic there.

When ABCA5 function is lost, those internal compartments do not work as cleanly. In studies of affected human hair follicles, cholesterol and partially digested cellular material build up inside cells when ABCA5 protein is dramatically reduced. That single observation has helped tie this gene to a rare inherited hair-growth condition and has opened questions about cancer prognosis and brain biology.

Inherited Hair Overgrowth

The clearest disease link for ABCA5 is a rare inherited condition called congenital generalized hypertrichosis terminalis, in which children are born with extensive thick hair across the body. Research identified a single DNA change at a splice site in intron 32 of ABCA5 that disrupts how the gene is read and dramatically lowers ABCA5 protein levels throughout patient hair follicles.

A separate large deletion of about 1.3 million base pairs of DNA on chromosome 17 that included ABCA5 produced a similar pattern, again with sharply reduced ABCA5 in hair follicles. The genetics of this condition are more complex than a simple recessive pattern: an autosomal recessive form occurs when both copies of ABCA5 are non-working, while autosomal dominant forms have also been described involving deletions and duplications in the same chromosomal region, likely through dosage effects or disruption of nearby regulatory elements. Carriers of a single loss-of-function variant in ABCA5 alone are generally not affected in the same way as those with biallelic loss.

Ovarian Cancer Survival

In high-grade serous epithelial ovarian cancer, a common ABCA5 variant called rs536009 has been linked to how long patients live after diagnosis. Women carrying the C-allele of this variant had about 50% higher risk of death from the disease (hazard ratio 1.50, 95% confidence interval 1.26 to 1.79) and shorter time before the cancer returned compared with other women in the same study.

The researchers were careful to note that strong genetic linkage in this region of the chromosome means rs536009 itself may not be the direct cause. It may simply travel alongside another variant that is doing the actual biological work. This finding applies to women already diagnosed with serous ovarian cancer, not to ovarian cancer risk in the general population.

Reconciling the Cancer Findings

The ovarian cancer data point in a direction that can feel confusing. Low ABCA5 expression inside tumors was tied to worse survival in patients whose cancer had been mostly removed by surgery. At the same time, ABCA5 has been identified as a putative marker of tumor stem cells in osteosarcoma, with additional reports of expression in poorly differentiated colon tumors and in chemoresistant laryngeal cancer cells. It is not among the broadly recognized cancer stem cell markers, and the evidence outside osteosarcoma remains limited. The same gene appears to play different roles in different cancer types, which is why a single number on a lab report cannot be read as universally good or bad. ABCA5 is better thought of as one piece of a broader cellular cholesterol-handling system whose effect depends on the tissue context.

Brain and Neurodegeneration Signals

ABCA5 is expressed strongly in the human brain, especially in neurons. ABCA5 messenger RNA is elevated in the brains of people with Parkinson's and in the hippocampus of people with Alzheimer's. Laboratory experiments raising ABCA5 levels reduced the build-up of amyloid-beta, the protein fragment that accumulates in Alzheimer's brains, by changing how its parent protein is processed. Some studies have flagged suggestive associations between ABCA5 variants and Parkinson's disease risk, but the gene has not reached genome-wide significance in the large Parkinson's GWAS meta-analyses, so any link should be considered exploratory rather than established.

These observations are early. They suggest ABCA5 sits somewhere in the wiring of neurodegeneration, but they do not yet support the idea that knowing your ABCA5 genotype can predict your personal risk of Parkinson's or Alzheimer's disease.

One-Time Result

Your ABCA5 genotype does not change. The DNA sequence you inherit at birth is the sequence you will have at 40 and at 80. There is no value in repeating this test on the same sample type unless the result needs confirmation by a different lab method.

What changes over your lifetime are the downstream signals that may be influenced by your genetic background. If a particular ABCA5 variant ever becomes clinically actionable for a condition you are at risk for, the relevant follow-up will be tracking the right phenotype tests (lipids, cancer screening, neurological assessments) at appropriate intervals, not retesting the genotype itself.

When Genetic Results Can Be Misleading

• Variant panel coverage: this assay reads specific positions in ABCA5. A result showing no risk variant does not rule out rarer variants in the same gene that the panel does not look for.
• Ancestry-specific allele frequencies: ABCA5 variants studied in one population may carry different risks or be absent in others. The clinical meaning of your result depends partly on your genetic background.
• Variants of uncertain significance: sequencing can occasionally reveal changes in ABCA5 that have not been classified as benign or harmful. These results often require expert interpretation and may need to be revisited as databases grow.
• Direct-to-consumer comparisons: if you have seen ABCA5 data on a consumer genomics report, the variants typed there may differ from a clinical-grade test, and direct comparisons can mislead.

What to Do With an Out-of-Pattern Result

If your ABCA5 result flags a variant tied to one of the known associations, the next steps depend on the variant and your situation. A confirmatory test by Sanger sequencing is reasonable if the original method was a SNP chip. A consultation with a genetic counselor can help you understand whether the finding has clear clinical implications or remains in the research category.

For biological relatives, knowing that ABCA5 variants exist in your family may be useful information to share, especially if multiple relatives have unusual hair growth patterns or rare ovarian cancers. Carrying a risk variant is not the same as developing the associated condition. Many people with risk variants never develop the disease, and many people without identified variants still can.